Your look at today’s health care headlines, including production challenges at a Aurobindo, Pfizer’s Super Bowl commercial, and Novo Nordisk’s semaglutide lawsuits.
Aurobindo—one of the largest generic drug manufacturers—is cutting production at a “key facility” in India, according to a report from STAT News. The halt comes after FDA inspectors identified 9 quality control issues at a plant in Telangana, India, with a number of production lines impacted. In a report filed by the company, they indicated their intention to work closely with the FDA and a continued commitment to compliance.
Pharmaceutical giant Pfizer scored a touchdown during the third quarter of Super Bowl LVIII with their 60-second “Here’s To Science” ad spot. The ad—estimated to cost nearly $14 million—set to Queen’s iconic anthem “Don’t Stop Me Now” featured scientific greats as far back as Archimedes as well as the more modern men and women who have made significant breakthroughs in the health care field. The game ended with a victory by the Kansas City Chiefs, 25-22, who scored the winning touchdown in overtime.
Late last week, semaglutide manufacturer Novo Nordisk settled 2 lawsuits against 2 businesses offering compounded versions of Ozempic and Wegovy. Both defendants—Cosmetic Laser professionals Med Spa and Nuvida Rx Weight Loss, located in Florida—are “permanently banned” from claiming that the compounded drugs on offer are FDA approved, as well as from using Novo Nordisk trademarks or logos on their products and from publishing any misleading advertising.
USA Today reported Emily Le Coz has published a report detailing the death of Ashleigh Anderson, a pharmacist who died of a heart attack while working at a CVS store in Seymour, Indiana. Anderson’s death has been highlighted by pharmacy activists who are advocating for better working conditions and other sweeping changes to address professional burnout.